Paul R. Kirchgraber, CEO, Covance Drug Development at LABORATORY CORP OF AMERICA HOLDINGS (LH), sold 8,000 shares at $250.58 ($2.0M) on 2023-02-21, disclosed to the SEC on 2023-02-23.
Seasonal sale ($2.0M) by CEO, Covance Drug Development — this insider has traded LH in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| Filing → |
| LH | SELL | 2020-11-06 | $321K | — | Filing → |